Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

Summary

This is a 2-part study consisting of a Part 1, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), or Recommended Part 2 Dose (RP2D) of LIS1 as a single agent; followed by a Part 2, to investigate anti-tumors efficacy of LIS1 in selected subtypes of Peripheral TCell Lymphoma (PTCL) and to further evaluate its safety and tolerability at RP2D.

Timeline

Start

2024-07-09

Primary completion

2026-07-31

Completion

2027-07-31

Drugs

Indications